G1 Therapeutics Says Initial Results From Phase 2 Mechanism Of Action Trial In Breast Cancer Show That Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

G1 Therapeutics Inc GTHX:

• INITIAL RESULTS FROM PHASE 2 MECHANISM OF ACTION TRIAL IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER SHOW THAT A SINGLE DOSE OF TRILACICLIB FAVORABLY ALTERS THE TUMOR MICROENVIRONMENT